INT J LAB HEMATOL:全血细胞计数的质量控制如何实现?

2019-01-21 MedSci MedSci原创

有效的医学实验室质量管理体系是确保分析和报告准确可靠的基石。为了保证质量,每个实验室都应该进行适当的内部质量控制(IQC)程序来监控他们的检测系统。卫生保健质量管理研究所(IQMH)能力测试中心进行了一项关于常规血液学质量控制(QC)实践的调查。 研究人员对安大略省184个实验室进行全血细胞计数(CBC)和白细胞差异的在线调查。结果所有受试者均采用三级商业QC进行测试系统监控。80%的实验室

有效的医学实验室质量管理体系是确保分析和报告准确可靠的基石。为了保证质量,每个实验室都应该进行适当的内部质量控制(IQC)程序来监控他们的检测系统。卫生保健质量管理研究所(IQMH)能力测试中心进行了一项关于常规血液学质量控制(QC)实践的调查。

研究人员对安大略省184个实验室进行全血细胞计数(CBC)和白细胞差异的在线调查。结果所有受试者均采用三级商业QC进行测试系统监控。80%的实验室对住院病人进行质量控制。质量控制分析的频率是可变的,主要由于:1. 制造商建议(80%)2.参数稳定性(25%)3.不正确结果的临床影响(21%)4.如果出现质量控制失败5. 可能需要重新测试的样本数量(11%)。所有实验室都使用既定的质量控制规则和限制来监控结果。采用了各种方法来建立限值,包括:1. QC结果的标准差(60%)2. 制造商精度目标(55%)3.公布精度目标(24%)4.IQMH允许性能限制(APLs)(37%)

本项研究结果表明,安大略省实验室的质量控制实践存在较大差异,应该进一步制定一致的实践建议和精确目标,以指导和规范质量控制。

原始出处:

Anna Johnston, Gini Bourner, Tracy Martin,Guidance for quality control practices and precision goals for CBCs based on IQMH patternsofpractice survey

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681845, encodeId=f555168184569, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Wed Feb 27 06:24:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863134, encodeId=12dd18631341f, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Aug 07 03:24:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317451, encodeId=cdfa131e451b2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jan 23 14:24:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681845, encodeId=f555168184569, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Wed Feb 27 06:24:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863134, encodeId=12dd18631341f, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Aug 07 03:24:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317451, encodeId=cdfa131e451b2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jan 23 14:24:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681845, encodeId=f555168184569, content=<a href='/topic/show?id=2fb489882cb' target=_blank style='color:#2F92EE;'>#血细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89882, encryptionId=2fb489882cb, topicName=血细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79127868468, createdName=ailian1211, createdTime=Wed Feb 27 06:24:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863134, encodeId=12dd18631341f, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Aug 07 03:24:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317451, encodeId=cdfa131e451b2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jan 23 14:24:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
    2019-01-23 医者仁心